Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 20, 2017
The Market Loves PayPal; Shares Now $70+
Image Shown: PayPal's stock has been a huge winner in the Best Ideas Newsletter portfolio. Payments processor PayPal reported fantastic third-quarter results and raised its full-year guidance for the third time in as many quarters. Shares are surging. Oct 19, 2017
Kinder Morgan’s Dividend Growth For Next Year Is Achievable; Here's Why
Image Source: Roy Luck. After its infamous dividend cut, Kinder Morgan is getting things back on track. We applaud management for its ability to bounce back from a tumultuous energy-resource pricing environment. Oct 19, 2017
Reimbursement Uncertainty Weighs on DaVita
Image Source: DaVita. DaVita has been left out in the cold with its share price losing ground in 2017 due to continued fears over reimbursement of care. Oct 19, 2017
IBM's Third Quarter Offers Some Relief
Image Shown: IBM rallies back after third-quarter results October 18. IBM has been shunned by investors since it bailed on its operating earnings per share target of $20 a few years ago. The market, however, was recently relieved that IBM reiterated its full-year 2017 expectations calling for operating earnings per share of at least $13.80. Many are hoping for a comeback. Oct 17, 2017
Netflix's Third Quarter Shows Free Cash Burn, More Debt
The Netflix app is displayed alongside other streaming media services on the homepage of a Roku Streaming Stick. (Photo credit: Matthew Keys / Flickr Creative Commons)Netflix is burning through free cash and the company’s balance sheet is ballooning with debt. The junk-rated company continues to attract buyers in this frothy stock market, however. Oct 15, 2017
Dividend Increases/Decreases for the Week Ending October 13
Let's take a look at companies raising/lowering their dividends this week. Oct 14, 2017
Euphoria Running Rampant: Investigating Some of the Hottest Names Around
Image Source: Tesla Roadster. As we march forward in what Morgan Stanley has dubbed a bull market of “epic proportions,” euphoria appears to be at levels perhaps not seen since the dot-com bust of the early 2000s. Let’s take a look at some of the “hottest” names on the market. Oct 12, 2017
An Overview on Valuing Junior Biotech Companies -- Does Clovis Fit the Bill?
The biotech industry remains one of the most fascinating yet perplexing industries for investors. Anecdotes of the entry-stage biotech with a home-run new therapy are often romanticized, but the reality is the vast majority of molecules fail in various stages of clinical testing. Due to the boom-bust nature of the industry, many are wary of investing in the space, and traditional valuation metrics are not as useful due to a large number of such speculative entities being in the pre-revenue stage. With this in mind, let’s take a glimpse into our thought process when evaluating upstart biotech companies. Oct 8, 2017
Dividend Increases/Decreases for the Week Ending October 6
Let's take a look at companies raising/lowering their dividends this week. Oct 5, 2017
The Bull Case for Airline Stocks?
Image Source: BriYYZ. Warren Buffett has famously said that airline stocks are horrible long-term investments, but his vast portfolio now owns a number of airlines. What’s the bull case for owning these capital-intensive, cyclical and often boom-and-bust stocks?
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353354355356357358359360 361362363364365366367368369370371372373374375376377378379380 381382383384385386387388389390391392393394395396397398399400 401402403404405406407408409410411412413414415416417418419420 421422423424425426427428429430431432433434435436437438439440 441442443444445446447448449450451452453454455456457458459460 461462463464465466467468469470471472473474475476477478479480 481482483484485486487488489490491492next The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|